Preparations are underway for a Phase 1b norovirus challenge study to evaluate our potent, oral antiviral candidate CDI-988 as a prophylaxis and ...

Cocrystal Pharma, Inc. announced an extension of enrollment in its Phase 2a human challenge study for the oral influenza PB2 inhibitor CDI-42344 due to unexpectedly low influenza infection rates ...

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025 Cocrystal Pharma’s pan ...

BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the ...

Cocrystal Pharma’s pan-viral protease inhibitor CDI-988 shows superior broad-spectrum antiviral activity against major norovirus variants including GII.4 and GII.17 strains ...

About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of ...

Cocrystal’s stock is trading at about $3.00, down from its pandemic high of $24.36 in 2021 and all-time high of $104.40 in 2017 (the company also announced reverse stock splits in 2022 and 2018).

--Cocrystal Pharma, Inc. announces that management will participate in a fireside chat during the Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference on Thursday, June 5, 2025 ...

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...

The firm has a market capitalization of $15.57 million, a price-to-earnings ratio of -0.83 and a beta of 2.35. Cocrystal Pharma has a 52-week low of $1.35 and a 52-week high of $3.26.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...